Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Aurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Torchia, Joshua Brody, Richard Luong, Michael D. Rosenblum, Lawrence Steinman, Hyam I. Levitsky, Victor Tse, Ronald Levy

Research output: Contribution to journalArticle

204 Citations (Scopus)

Abstract

Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

Original languageEnglish (US)
Pages (from-to)2447-2463
Number of pages17
JournalJournal of Clinical Investigation
Volume123
Issue number6
DOIs
StatePublished - Jun 3 2013

Fingerprint

Neoplasms
Immunomodulation
Immunotherapy
Lymphoma
Therapeutics
Nucleotides
Neoplasm Metastasis
Injections
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., ... Levy, R. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. Journal of Clinical Investigation, 123(6), 2447-2463. https://doi.org/10.1172/JCI64859

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. / Marabelle, Aurélien; Kohrt, Holbrook; Sagiv-Barfi, Idit; Ajami, Bahareh; Axtell, Robert C.; Zhou, Gang; Rajapaksa, Ranjani; Green, Michael R.; Torchia, James; Brody, Joshua; Luong, Richard; Rosenblum, Michael D.; Steinman, Lawrence; Levitsky, Hyam I.; Tse, Victor; Levy, Ronald.

In: Journal of Clinical Investigation, Vol. 123, No. 6, 03.06.2013, p. 2447-2463.

Research output: Contribution to journalArticle

Marabelle, A, Kohrt, H, Sagiv-Barfi, I, Ajami, B, Axtell, RC, Zhou, G, Rajapaksa, R, Green, MR, Torchia, J, Brody, J, Luong, R, Rosenblum, MD, Steinman, L, Levitsky, HI, Tse, V & Levy, R 2013, 'Depleting tumor-specific Tregs at a single site eradicates disseminated tumors', Journal of Clinical Investigation, vol. 123, no. 6, pp. 2447-2463. https://doi.org/10.1172/JCI64859
Marabelle, Aurélien ; Kohrt, Holbrook ; Sagiv-Barfi, Idit ; Ajami, Bahareh ; Axtell, Robert C. ; Zhou, Gang ; Rajapaksa, Ranjani ; Green, Michael R. ; Torchia, James ; Brody, Joshua ; Luong, Richard ; Rosenblum, Michael D. ; Steinman, Lawrence ; Levitsky, Hyam I. ; Tse, Victor ; Levy, Ronald. / Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 6. pp. 2447-2463.
@article{e524bfde9f324fb6aa45c529c9e18a04,
title = "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors",
abstract = "Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.",
author = "Aur{\'e}lien Marabelle and Holbrook Kohrt and Idit Sagiv-Barfi and Bahareh Ajami and Axtell, {Robert C.} and Gang Zhou and Ranjani Rajapaksa and Green, {Michael R.} and James Torchia and Joshua Brody and Richard Luong and Rosenblum, {Michael D.} and Lawrence Steinman and Levitsky, {Hyam I.} and Victor Tse and Ronald Levy",
year = "2013",
month = "6",
day = "3",
doi = "10.1172/JCI64859",
language = "English (US)",
volume = "123",
pages = "2447--2463",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

AU - Marabelle, Aurélien

AU - Kohrt, Holbrook

AU - Sagiv-Barfi, Idit

AU - Ajami, Bahareh

AU - Axtell, Robert C.

AU - Zhou, Gang

AU - Rajapaksa, Ranjani

AU - Green, Michael R.

AU - Torchia, James

AU - Brody, Joshua

AU - Luong, Richard

AU - Rosenblum, Michael D.

AU - Steinman, Lawrence

AU - Levitsky, Hyam I.

AU - Tse, Victor

AU - Levy, Ronald

PY - 2013/6/3

Y1 - 2013/6/3

N2 - Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

AB - Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

UR - http://www.scopus.com/inward/record.url?scp=84878567974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878567974&partnerID=8YFLogxK

U2 - 10.1172/JCI64859

DO - 10.1172/JCI64859

M3 - Article

C2 - 23728179

AN - SCOPUS:84878567974

VL - 123

SP - 2447

EP - 2463

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -